schliessen

Filtern

 

Bibliotheken

CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients

Backround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer. 330 gastric ca... Full description

Journal Title: Oncotarget 21 March 2017, Vol.8(12), pp.20328-20339
Main Author: Cao, Yifan
Other Authors: Liu, Hao , Zhang, Heng , Lin, Chao , Li, Ruochen , Wu, Songyang , Li, He , He, Hongyong , Zhang, Weijuan , Xu, Jiejie
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1949-2553 ; PMID: 27780937 Version:1 ; DOI: 10.18632/oncotarget.12815
Link: http://pubmed.gov/27780937
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline27780937
title: CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
format: Article
creator:
  • Cao, Yifan
  • Liu, Hao
  • Zhang, Heng
  • Lin, Chao
  • Li, Ruochen
  • Wu, Songyang
  • Li, He
  • He, Hongyong
  • Zhang, Weijuan
  • Xu, Jiejie
subjects:
  • Cxcr1
  • Adjuvant Chemotherapy
  • Gastric Cancer
  • Nomogram
  • Overall Survival
  • Biomarkers, Tumor -- Analysis
  • Receptors, Interleukin-8a -- Metabolism
  • Stomach Neoplasms -- Pathology
ispartof: Oncotarget, 21 March 2017, Vol.8(12), pp.20328-20339
description: Backround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer. 330 gastric cancer patients who underwent R0 gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital, Fudan University between 2007 and 2008 were enrolled. CXCR1 expression was evaluated with use of immunohistochemical staining. The relation between CXCR1 expression and clinicopathological features and postoperative prognosis was respectively inspected. In both discovery and validation data sets, CXCR1 high expression indicated poorer overall survival (OS) in TNM II and III patients. Furthermore, multivariate analysis identified CXCR1 expression and TNM stage as two independent prognostic factors for OS. Incorporating CXCR1 expression into current TNM staging system could generate a novel clinical predictive model for gastric cancer, showing better prognostic accuracy with respect to patients' OS. More importantly, TNM II patients with higher CXCR1 expression were shown to significantly benefit from postoperative 5-fluorouracil (5-FU) based adjuvant chemotherapy (ACT). CXCR1 in gastric cancer was identified as an independent adverse prognostic factor. Combining CXCR1 expression with current TNM staging system could lead to better risk stratification and more accurate prognosis for gastric cancer patients. High expression of CXCR1 identified a subgroup of TNM stage II gastric cancer patients who appeared to benefit from 5-FU based ACT.
language: eng
source:
identifier: E-ISSN: 1949-2553 ; PMID: 27780937 Version:1 ; DOI: 10.18632/oncotarget.12815
fulltext: fulltext
issn:
  • 19492553
  • 1949-2553
url: Link


@attributes
ID43222017
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid27780937
sourceidmedline
recordidTN_medline27780937
sourceformatXML
sourcesystemPC
pqid1835687470
display
typearticle
titleCXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
creatorCao, Yifan ; Liu, Hao ; Zhang, Heng ; Lin, Chao ; Li, Ruochen ; Wu, Songyang ; Li, He ; He, Hongyong ; Zhang, Weijuan ; Xu, Jiejie
ispartofOncotarget, 21 March 2017, Vol.8(12), pp.20328-20339
identifier
subjectCxcr1 ; Adjuvant Chemotherapy ; Gastric Cancer ; Nomogram ; Overall Survival ; Biomarkers, Tumor -- Analysis ; Receptors, Interleukin-8a -- Metabolism ; Stomach Neoplasms -- Pathology
descriptionBackround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer. 330 gastric cancer patients who underwent R0 gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital, Fudan University between 2007 and 2008 were enrolled. CXCR1 expression was evaluated with use of immunohistochemical staining. The relation between CXCR1 expression and clinicopathological features and postoperative prognosis was respectively inspected. In both discovery and validation data sets, CXCR1 high expression indicated poorer overall survival (OS) in TNM II and III patients. Furthermore, multivariate analysis identified CXCR1 expression and TNM stage as two independent prognostic factors for OS. Incorporating CXCR1 expression into current TNM staging system could generate a novel clinical predictive model for gastric cancer, showing better prognostic accuracy with respect to patients' OS. More importantly, TNM II patients with higher CXCR1 expression were shown to significantly benefit from postoperative 5-fluorouracil (5-FU) based adjuvant chemotherapy (ACT). CXCR1 in gastric cancer was identified as an independent adverse prognostic factor. Combining CXCR1 expression with current TNM staging system could lead to better risk stratification and more accurate prognosis for gastric cancer patients. High expression of CXCR1 identified a subgroup of TNM stage II gastric cancer patients who appeared to benefit from 5-FU based ACT.
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/27780937$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Cao, Yifan
1Liu, Hao
2Zhang, Heng
3Lin, Chao
4Li, Ruochen
5Wu, Songyang
6Li, He
7He, Hongyong
8Zhang, Weijuan
9Xu, Jiejie
titleCXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
description
0Backround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer.
1330 gastric cancer patients who underwent R0 gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital, Fudan University between 2007 and 2008 were enrolled. CXCR1 expression was evaluated with use of immunohistochemical staining. The relation between CXCR1 expression and clinicopathological features and postoperative prognosis was respectively inspected.
2In both discovery and validation data sets, CXCR1 high expression indicated poorer overall survival (OS) in TNM II and III patients. Furthermore, multivariate analysis identified CXCR1 expression and TNM stage as two independent prognostic factors for OS. Incorporating CXCR1 expression into current TNM staging system could generate a novel clinical predictive model for gastric cancer, showing better prognostic accuracy with respect to patients' OS. More importantly, TNM II patients with higher CXCR1 expression were shown to significantly benefit from postoperative 5-fluorouracil (5-FU) based adjuvant chemotherapy (ACT).
3CXCR1 in gastric cancer was identified as an independent adverse prognostic factor. Combining CXCR1 expression with current TNM staging system could lead to better risk stratification and more accurate prognosis for gastric cancer patients. High expression of CXCR1 identified a subgroup of TNM stage II gastric cancer patients who appeared to benefit from 5-FU based ACT.
subject
0Cxcr1
1Adjuvant Chemotherapy
2Gastric Cancer
3Nomogram
4Overall Survival
5Biomarkers, Tumor -- Analysis
6Receptors, Interleukin-8a -- Metabolism
7Stomach Neoplasms -- Pathology
general
027780937
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.18632/oncotarget.12815
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline27780937
issn
019492553
11949-2553
rsrctypearticle
creationdate2017
addtitleOncotarget
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr4120170321
citationpf 20328 vol 8 issue 12
startdate20170321
enddate20170321
lsr30VSR-Enriched:[pqid]
sort
titleCXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
authorCao, Yifan ; Liu, Hao ; Zhang, Heng ; Lin, Chao ; Li, Ruochen ; Wu, Songyang ; Li, He ; He, Hongyong ; Zhang, Weijuan ; Xu, Jiejie
creationdate20170321
lso0120170321
facets
frbrgroupid-2775972568176389950
frbrtype5
newrecords20190701
languageeng
creationdate2017
topic
0Cxcr1
1Adjuvant Chemotherapy
2Gastric Cancer
3Nomogram
4Overall Survival
5Biomarkers, Tumor–Analysis
6Receptors, Interleukin-8a–Metabolism
7Stomach Neoplasms–Pathology
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Cao, Yifan
1Liu, Hao
2Zhang, Heng
3Lin, Chao
4Li, Ruochen
5Wu, Songyang
6Li, He
7He, Hongyong
8Zhang, Weijuan
9Xu, Jiejie
jtitleOncotarget
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Cao
1Liu
2Zhang
3Lin
4Li
5Wu
6He
7Xu
aufirst
0Yifan
1Hao
2Heng
3Chao
4Ruochen
5Songyang
6He
7Hongyong
8Weijuan
9Jiejie
au
0Cao, Yifan
1Liu, Hao
2Zhang, Heng
3Lin, Chao
4Li, Ruochen
5Wu, Songyang
6Li, He
7He, Hongyong
8Zhang, Weijuan
9Xu, Jiejie
atitleCXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
jtitleOncotarget
risdate20170321
volume8
issue12
spage20328
pages20328-20339
issn1949-2553
eissn1949-2553
formatjournal
genrearticle
ristypeJOUR
abstractBackround: Abnormal expression of CXC chemokine receptor 1 (CXCR1) has shown the ability to promote tumor angiogensis, invasion and metastasis in several cancers. The purpose of our curret study is to discover the clinical prognostic significance of CXCR1 in resectable gastric cancer.
doi10.18632/oncotarget.12815
pmid27780937
date2017-03-21